Short-term androgen deprivation therapy and high-dose radiotherapy in intermediate- and high-risk localized prostate cancer: Results from the GETUG 14 randomized phase III trial - 20/11/24
, P. Sargos 2, N. Sahki 3, S. Guérif 4, R. De Crevoisier 5, G. Calais 6, J.M. Hannoun Levi 7, G. Bouche 8, C. Hennequin 9, J. Cretin 10, Y. Belkacemi 11, J. Khalifa 12, D. Azria 13, A. Grandgirard 14, P. Pommier 15, J.M. Simon 16, C. Leger 17, V. Beckendorf 1, B. Dubray 18, S. Supiot 19Résumé |
Introduction |
Few studies compared short-term androgen deprivation (STADT) with high-dose radiotherapy (STADT-RT) versus high dose radiotherapy (RT) alone in localized prostate cancer.
Methods |
The GETUG 14 study randomized 376 patients between RT (n=191) and STADT-RT (n=179). RT dose was 80Gy in both arms and STADT was 4-month flutamide, starting 2 months before irradiation and 4-month triptorelin, starting with irradiation. Disease-free survival (DFS) was the primary endpoint. Secondary endpoints were overall survival (OS), biochemical failure-free survival (BFFS), metastasis-free survival (MFS), toxicity and quality of life.
Results |
With a median follow-up of 84 months, five-year DFS was 76% in RT arm versus 84% in STADT-RT arm (hazard radio (HR)=0.64; (95% CI 0.43–0.89); P=0.02). ADT had a positive impact on BFS (HR=0.45; P=0.001) and MFS (HR=0.5; P=0.09) but not on OS (HR=1.22; P=0.54). No difference was fond in terms of gastro intestinal (26% of grade>1 in both arm, P=0.97) and genito-urinary toxicity (39% for RT and 42% for STADT-RT, P=0.55). Similarly, no difference was found in quality of life.
Conclusion |
STADT improves DFS in intermediate and high-risk prostate cancer patients receiving high dose (80Gy) RT, without any deterioration in the safety profile.
Le texte complet de cet article est disponible en PDF.Plan
Vol 34 - N° 7S
P. S36 - novembre 2024 Retour au numéro
Article précédent
- HIFU vs prostatectomie totale : résultats carcinologiques de l’étude HIFI (3328 patients)
- G. Ploussard, G. Fiard, T. Chevallier, M. Baboudjian, R. Mathieu, N. Houede, A. Villers, P. Coloby, P. Rischmann
- Apport de l’olfaction canine dans la stratégie diagnostique du cancer de prostate à risque intermédiaire ou élevé : une étude de validation en double aveugle
- M. Hermieu, A. Roux, L. Desquilbet, N. Hermieu, C. Gallet, E. Xylinas, A. De La Taille, D. Grandjean, J.F. Hermieu
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?